Treatment of Von Willebrand's Disease

Logan, L. J.

doi:10.1016/s0889-8588(18)30295-8

Cited by 8 publications

(8 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reports of successful use of Hae mate P in vWD were also published by Scharrer and Vigh [5], Takahashi et al [6], Czapek et al [7], Fukui et al [1], Vigh et al [8], Berntorp and Nilsson [2], Ieko et al [9], Rose et al [10], Logan [11], Mannucci et al [12], Rodeghiero et al [13], Yoshioka et al [14], and Foster [15], Several other new FVIII concentrates look promising for treatment of vWD. Successful use of SD-FVIII concentrates and other FVIII preparations were reported by Furlan et al [16], Gazengel et al [ 17], Mazurier et al [18], Logan and Higgins [ 19], Pasi et al [20], Palmer et al [21], Cumming et al [22], Lawrie et al [23], Oates et al [24], Retzios et al [25], and Hanna et al [26].…”

mentioning

confidence: 97%

Experience with Haemate P in von Willebrand’s Disease in Adults

Scharrer¹,

Vigh²,

Aygören‐Pürsün³

1994

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

The virally inactivated pasteurized FVIII concentrate Haemate P contains nearly intact vWF multimers. It is currently the treatment of choice to achieve satisfactory hemostasis for moderate to severe vWD and for patients with variants of vWD that cannot be adequately treated with DDAVP or for whom DDAVP is contraindicated. Therefore, we treated patients with type la, type IIa, type IIb and type III vWD with Haemate P. A correction of the hemostatic defect was seen in all patients. The type of bleeding events included 24 gastrointestinal, 18 other mucosal, 5 central nervous system, 15 orthopedic and other. 28 dental surgical procedures, 9 operative deliveries, tonsillectomies, 17 orthopedic and 11 miscellaneous surgeries were performed under the cover of Haemate P.

show abstract

mentioning

confidence: 97%

Experience with Haemate P in von Willebrand’s Disease in Adults

Scharrer¹,

Vigh²,

Aygören‐Pürsün³

1994

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

show abstract

“…However, bleeding episodes in some of these patients can be managed by stimulating the release of factor VIII and vWF from storage sites through the use of desmopressin acetate (DDAVP), a synthetic analogue of the pituitary hormone vasopressin [1,2,5,6]. In the late 1970s, intravenous administration of DDAVP was demonstrated to raise levels of factor VIII and vWF, thereby controlling bleeding in patients with mild to moderate haemophilia A or type 1 vWD [1–8]. High‐dose DDAVP intranasal spray (Stimate ® ; 1.5 mg mL –1 ), is a concentrated preparation of DDAVP that is designed for intranasal administration to patients with mild haemophilia A or type 1 vWD who have factor VIII levels greater than 5%.…”

mentioning

confidence: 99%

High‐dose DDAVP intranasal spray (Stimate^®) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A

et al. 2001

View full text Add to dashboard Cite

An open-label multicentre trial was conducted to evaluate high-dose DDAVP (desmopressin acetate) intranasal spray (Stimate; 1.5 mg mL(-1)), for the control of bleeding in 333 patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease, or symptomatic carriers of haemophilia A. Overall, 278 patients received 2170 doses of high-dose DDAVP intranasal spray (1.5 mg mL(-1)). Using study-defined guidelines, patients evaluated the efficacy of high-dose DDAVP intranasal spray (1.5 mg mL(-1)) as 'excellent' or 'good' in 743 (95%) of 784 bleeding episodes. It demonstrated 'excellent' results in 384 (93%) of 413 administrations for prophylaxis and in eight of eight uses prior to acute surgical or dental procedures. When used for the treatment of menorrhagia, the efficacy of high-dose DDAVP intranasal spray (1.5 mg mL(-1)) was rated as 'excellent' after 655 (92%) of 721 daily uses. Of 2170 doses of high-dose DDAVP intranasal spray (1.5 mg mL(-1)), 172 (8%) were associated with adverse events. A total of 272 adverse events were reported among 80 patients. Of these, 239 (88%) were mild or moderate in intensity and only one patient was removed from the study due to an adverse event. These results demonstrate the safety and efficacy of high-dose DDAVP intranasal spray (1.5 mg mL(-1)) for control of bleeding episodes in patients with mildly decreased levels of factor VIII, von Willebrand factor, or both.

show abstract

“…DDAVP, at a dose of 0.3 μg/kg, is diluted in 10 to 50 mL of saline, and is administered intravenously over 15 to 30 minutes. 44 Antifibrinolytic therapy is particularly helpful in the treatment of oral hemorrhage because saliva contains a high concentration of fibrinolytic proteins, so clot formation is rendered more difficult. 3 DDAVP can rarely cause inappropriate water retention and subsequent hyponatremia that can be avoided with fluid restriction after treatment.…”

Section: Nonconcentrate Therapeutic Options For Hemophiliamentioning

confidence: 99%

“…However, if other alternatives are not available, transfusion of cryoprecipitate will produce hemostasis. 44 In addition, highpurity plasma-derived (monoclonal antibody-derived) FVIII as well as rFVIII cannot be used to treat vWD because they do not contain appreciable amounts of vWF. 90,98 Cryoprecipitate from a single donor who has been pretreated with DDAVP contains supraphysiologic amounts of vWF and is another treatment option.…”

Section: Exogenous Von Willebrand Factor Replacementmentioning

confidence: 99%